TuisRLFTF • OTCMKTS
add
RELIEF THERAPEUTICS Holding SA
Vorige sluiting
$3,04
Dagwisseling
$2,62 - $2,70
Jaarwisseling
$1,10 - $7,66
Markkapitalisasie
31,73 m CHF
Gemiddelde volume
1,62 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,38 m | -8,21% |
Bedryfskoste | 2,63 m | -48,44% |
Netto inkomste | -6,28 m | 69,86% |
Netto winsgrens | -454,65 | 67,17% |
Wins per aandeel | — | — |
EBITDA | -1,45 m | 58,14% |
Effektiewe belastingkoers | 18,21% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 15,08 m | 3,54% |
Totale bates | 53,22 m | -30,33% |
Totale aanspreeklikheid | 16,56 m | -31,46% |
Totale ekwiteit | 36,66 m | — |
Uitstaande aandele | 12,54 m | — |
Prys om te bespreek | 1,04 | — |
Opbrengs op bates | -7,07% | — |
Opbrengs op kapitaal | -9,70% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -6,28 m | 69,86% |
Kontant van bedrywe | 125,00 k | 103,50% |
Kontant van beleggings | 2,20 m | -50,56% |
Kontant van finansiering | -123,00 k | -98,39% |
Netto kontantverandering | 2,18 m | 146,71% |
Beskikbare kontantvloei | 1,25 m | -47,41% |
Meer oor
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Gestig
2013
Webwerf
Werknemers
31
